Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE INSYS THERAPEUTICS, INC. SECURITIES LITIGATION
Case Number:
1:17-cv-01954
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
-
March 04, 2019
Insys Investors Seek Cert. In Fentanyl Stock Drop Suit
Insys Therapeutics Inc. investors urged a New York federal judge Friday to certify their putative class action accusing the pharmaceutical company of overstating its opioid spray's financial strength, a move that sparked a stock downturn once the accounting problems were revealed.
-
June 13, 2018
Insys Can't Duck Investor Suit Over Opioid Spray's Financials
Insys Therapeutics Inc. and its top brass largely lost their bid to boot an investor's fraud suit Tuesday when a New York federal judge found the complaint had adequately tied the company's alleged misstatements to a concrete loss, allowing the proposed shareholder action accusing Insys of overstating its fentanyl spray's financial strength to move forward.
-
November 07, 2017
Pharma Co. Behind Fentanyl Spray Seeks Out Of Investor Suit
Specialty pharmaceutical company Insys Therapeutics Inc. has urged a New York federal court to toss a proposed class action accusing it of seeking to cover up declining revenues from its fentanyl-based pain medication Subsys, saying that the investors behind the suit are making a mountain out of a molehill.
-
June 01, 2017
Levi & Korsinsky Will Lead Insys Shareholder Suit
The plaintiffs firm Levi & Korsinsky LLP was selected by a New York federal judge on Wednesday to represent investors who accuse Insys Therapeutics Inc. of securities fraud over a possible $5 million accounting error that the pharmaceutical company disclosed in March.
-
March 17, 2017
Pain Drug Co. Insys Faces Stock-Drop Suit After Audit News
Insys Therapeutics Inc., a publicly traded company that sells and develops pain treatments for people with cancer and epilepsy, was hit with a potential securities fraud class action in New York on Friday after its stock dropped when it said it may have overstated past revenues by $5 million.